

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pype et al.

Serial No.: To be assigned

Filed: January 15, 2004

For: CD40-INTERACTING AND TRAF-
INTERACTING PROTEINS

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2676-4555.1US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV325783810US

Date of Deposit with USPS: January 15, 2004

Person making Deposit: Christopher Haughton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Foreign Patent Documents

| <u>Document No.</u> | <u>Publication Date</u> | <u>Patentee</u> |
|---------------------|-------------------------|--|
| #WO 96/16665 | 06-06-1996 | La Jolla Cancer Research Foundation |
| #WO 96/18639 | 06-20-1996 | The John Hopkins University School of Medicine |
| #WO 96/34473 | 09-25-1997 | Trustees of Columbia University |
| #WO 97/34946 | 08-13-1998 | Massachusetts Institute of Technology |
| #JP 11-75856 | 03-23-1999 | Nippon Shoji KK |
| #WO 99/33869 | 07-08-1999 | Corixa Corporation |
| #WO 99/55859 | 11-04-1999 | Vlaams Interuniversitair Instituut voor Biotechnologie VZW |

Other Documents

#Abstract XP-002115104, Pye et al., 3.13 "Identification of a Novel CD40 Interacting Protein", 1 page.

#Abstract XP-002115105, Derwent Publications Ltd., "New Topoisomerase II-binding protein - useful as an anticancer agent", 1 page.

#HANISSIAN et al., "Jak3 Is Associated with CD40 and is Critical for CD40 Induction of Gene Expression in B Cells", Immunity, Vol. 5, pp. 379-387, April, 1997.

#PCT International Search Report, PCT/EP99/03025, dated September 30, 1999, 8 pages.

#PCT International Preliminary Examination Report, PCT/EP99/03025, dated July 24, 2000.

#ROTHER et al., "A Novel Family of Putative Signal Transducers Associated with the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor", Cell, Vol. 78, pp. 681-692, August 26, 1994.

#YANG et al., "Daxx, a Novel Fas-Binding Protein That Activates JNK and Apoptosis",
Cell, Vol. 89, pp. 1067-1076, June 27, 1997

#GELIBERT et al., The involvement of multiple tumor necrosis factor receptor (TNFR)-
associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of
the TNFR superfamily, 1998, J. Biol. Chem. pp. 34120-27, Vol. 273.

#HONIG, B, Protein folding: from the levinthal paradox to struture prediction, 1999, J.
Mol. Biol. , pp. 283-93, Vol. 293.

#GREEN et al., Identification of a novel vertebrate circadian clock-regulated gene
encoding the protein nocturnin, 1996, Proc. Natl. Acad. Sci., pp. 14884-88, Vol. 93, USA.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the
Office in the following prior application:

Serial No.: 09/697,863

Filed: October 27, 2000

For: CD40-Interacting and Traf-Interacting Proteins, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to
37 C.F.R. § 1.56 & 1.175, Applicants offer hereby identifies the following listed copending
applications naming the same inventor(s):

Attorney Docket No.: 2676-4359US
Serial No.: 09/553,789
Filing Date: 4/21/2000
Title: INDUCIBLE CELLULAR IMMUNITY THROUGH ACTIVATION
OF TH1 AND SUPPRESSION OF TH2 RESPONSES BY
MACROPHAGES

Attorney Docket No.: 2676-4555US
Serial No.: 09/697,863
Filing Date: 10/27/2000
Title: CD40-INTERACTING AND TRAF-INTERACTING PROTEINS


Attorney Docket No.: 2676-4232.1US
Serial No.: 09/964,238
Filing Date: 9/26/2001
Title: SMAD-INTERACTING POLYPEPTIDES AND THEIR USE

Attorney Docket No.: 2676-4555.1US

Attorney Docket No.: 2676-5174US
Serial No.: 10/028,396
Filing Date: 12/21/2001
Title: NUCLEIC ACID BINDING OF MULTI-ZINC TRANSCRIPTION
FACTORS

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Allen C. Turner", with a long horizontal stroke extending to the right.

Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: January 15, 2004
ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Cited Documents

Document in ProLaw

| | | | | | |
|---|---|----|---|--------------------------|------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | To be assigned |
| | | | | Filing Date | January 15, 2004 |
| | | | | First Named Inventor | Pype et al. |
| | | | | Group Art Unit | To be assigned |
| | | | | Examiner Name | To be assigned |
| Sheet | 1 | of | 2 | Attorney Docket Number | 2676-4555.1US |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | #WO 96/16665 | 06-06-1996 | La Jolla Cancer Research Foundation | | |
| | | #WO 96/18639 | 06-20-1996 | The John Hopkins University School of Medicine | | |
| | | #WO 96/34473 | 09-25-1997 | Trustees of Columbia University | | |
| | | #WO 97/34946 | 08-13-1998 | Massachusetts Institute of Technology | | |
| | | #JP 11-75856 | 03-23-1999 | Nippon Shoji KK | | |
| | | #WO 99/33869 | 07-08-1999 | Corixa Corporation | | |
| | | #WO 99/55859 | 11-04-1999 | Vlaams Interuniversitair Instituut voor Biotechnologie VZW | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|------------------|
| Application Number | To be assigned |
| Filing Date | January 15, 2004 |
| First Named Inventor | Pype et al. |
| Group Art Unit | To be assigned |
| Examiner Name | To be assigned |
| Attorney Docket Number | 2676-4555 IUS |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | | #Abstract XP-002115104, Pype et al., 3.13 "Identification of a Novel CD40 Interacting Protein", 1 page. | |
| | | #Abstract XP-002115105, Derwent Publications Ltd., "New Topoisomerase II-binding protein - useful as an anticancer agent", 1 page. | |
| | | #HANISSIAN et al., "Jak3 Is Associated with CD40 and is Critical for CD40 Induction of Gene Expression in B Cells", Immunity, Vol. 5, pp. 379-387, April, 1997. | |
| | | #PCT International Search Report, PCT/EP99/03025, dated September 30, 1999, 8 pages. | |
| | | #PCT International Preliminary Examination Report, PCT/EP99/03025, dated July 24, 2000. | |
| | | #ROTHE et al., "A Novel Family of Putative Signal Transducers Associated with the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor", Cell, Vol. 78, pp. 681-692, August 26, 1994. | |
| | | #YANG et al., "Daxx, a Novel Fas-Binding Protein That Activates JNK and Apoptosis", Cell, Vol. 89, pp. 1067-1076, June 27, 1997 | |
| | | #GELIBERT et al., The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily, 1998, J. Biol. Chem. pp. 34120-27, Vol. 273. | |
| | | #HONIG, B, Protein folding: from the levinthal paradox to structure prediction, 1999, J. Mol. Biol. , pp. 283-93, Vol. 293. | |
| | | #GREEN et al., Identification of a novel vertebrate circadian clock-regulated gene encoding the protein nocturnin, 1996, Proc. Natl. Acad. Sci., pp. 14884-88, Vol. 93, USA. | |
| | | | |

Examiner
SignatureDate
Considered

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/697,863

Filed: October 27, 2000

For: CD40-Interacting and Traf-Interacting Proteins, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.